ArticleFrontiers in medicine2026
Identification and validation of biomarkers of Shenggu Zaizao Wan in the treatment of steroid-induced osteonecrosis of the femoral head by integrating network pharmacology and bulk transcriptomic.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Steroid-induced osteonecrosis of the femoral head (SONFH) is a debilitating condition. Research has shown that Shenggu Zaizao Wan (SZW) may have therapeutic effects on SONFH. This study aimed to elucidate the mechanisms by which SZW treats SONFH. Methods: SONFH and control samples were retrieved from a database to identify differentially expressed genes (DEGs). Biomarkers were obtained through the intersection of DEGs and potential targets, machine learning, and expression validation. A nomogram was constructed, followed by gene set enrichment analysis (GSEA) of biomarkers and immune infiltration analysis. Molecular docking was conducted, and the expression of biomarkers was evaluated using real-time quantitative reverse transcription PCR (RT-qPCR). Results: A total of 69 potential SZW targets and 1,671 DEGs were identified. IKBKB and PRKCA were established as biomarkers for SONFH, and a nomogram was developed. GSEA indicated that IKBKB and PRKCA may influence pathways related to the ribosome. Immune infiltration analysis revealed that CD4 Conclusion: This study identified IKBKB and PRKCA as potential biomarkers and targets for SZW treatment in SONFH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.